Bristol/AZ Saxagliptin Review Deadline Pushed Back; Tea Leaves Still Look Good For Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol and FDA are working on cardiovascular outcomes study proposal. New deadline is July 30.